Advanced Solid Tumors
Conditions
Interventions
None listed
Sponsors
BeOne Medicines I GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Outcome results
None listed
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors
For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms
Source: EU CTIS · Data processed: May 1, 2026